Abstract
A median safinamide (SAF) dose of 70 mg/day (range 40 to 90 mg/day) increased the percentage of parkinsonian patients improving their motor scores by > or =30% from baseline (responders) after 3 months from 21.4% (placebo) to 37.5% (p < 0.05, calculated by logistic regression analysis). In a subgroup of 101 patients under stable treatment with a single dopamine agonist, addition of SAF magnified the response (47.1% responders, mean 4.7-point motor score decrease; p > or = 0.05). These results suggest that doses of SAF exerting ion channel block and glutamate release inhibition add to its symptomatic effect and warrant exploration of higher doses.
Publication types
-
Clinical Trial
-
Multicenter Study
-
Randomized Controlled Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Aged
-
Alanine / administration & dosage
-
Alanine / adverse effects
-
Alanine / analogs & derivatives*
-
Alanine / pharmacology
-
Alanine / therapeutic use*
-
Antiparkinson Agents / administration & dosage
-
Antiparkinson Agents / adverse effects
-
Antiparkinson Agents / pharmacology
-
Antiparkinson Agents / therapeutic use*
-
Benzylamines / administration & dosage
-
Benzylamines / adverse effects
-
Benzylamines / pharmacology
-
Benzylamines / therapeutic use*
-
Calcium Channel Blockers / administration & dosage
-
Calcium Channel Blockers / adverse effects
-
Calcium Channel Blockers / pharmacology
-
Calcium Channel Blockers / therapeutic use
-
Dopamine Agonists / pharmacology
-
Dopamine Agonists / therapeutic use*
-
Dose-Response Relationship, Drug
-
Double-Blind Method
-
Drug Synergism
-
Drug Therapy, Combination
-
Excitatory Amino Acid Antagonists / administration & dosage
-
Excitatory Amino Acid Antagonists / adverse effects
-
Excitatory Amino Acid Antagonists / pharmacology
-
Excitatory Amino Acid Antagonists / therapeutic use
-
Female
-
Gastrointestinal Diseases / chemically induced
-
Glutamic Acid / metabolism
-
Humans
-
Male
-
Middle Aged
-
Motor Activity / drug effects*
-
Neuroprotective Agents / administration & dosage
-
Neuroprotective Agents / adverse effects
-
Neuroprotective Agents / pharmacology
-
Neuroprotective Agents / therapeutic use*
-
Parkinson Disease / drug therapy*
-
Parkinson Disease / physiopathology
-
Sodium Channel Blockers / administration & dosage
-
Sodium Channel Blockers / adverse effects
-
Sodium Channel Blockers / pharmacology
-
Sodium Channel Blockers / therapeutic use
-
Treatment Outcome
Substances
-
Antiparkinson Agents
-
Benzylamines
-
Calcium Channel Blockers
-
Dopamine Agonists
-
Excitatory Amino Acid Antagonists
-
Neuroprotective Agents
-
Sodium Channel Blockers
-
Glutamic Acid
-
safinamide
-
Alanine